Suchergebnisse - (Subject:"Siltuximab")

PubPharm (16)

1

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID) : a factorial, randomised, controlled trial

enthalten in: The Lancet. Respiratory medicine | 2021

von Declercq, J. | Van Damme, K. | De Leeuw, E. | +40

CommentIn: Lancet Respir Med. 2021 Dec;9(12):1353-1354. - PMID 34756179

2

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease : a prespecified, open-label, extension analysis of two trials

enthalten in: The Lancet. Haematology | 2020

von van Rhee, F. | Casper, C. | Voorhees, P. | +4

3

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Brighton, T. | Khot, A. | Harrison, S. | +15

4

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

5

Siltuximab in relapsed/refractory multicentric Castleman disease : Experience of the Italian NPP program

enthalten in: Hematological oncology | 2018

von Tonialini, L. | Bonfichi, M. | Ferrero, S. | +4

6

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma : an open-label phase I trial

enthalten in: Blood cancer journal | 2016

von Shah, J. | Feng, L. | Thomas, S. | +8

7

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

enthalten in: Oncotarget | 2015

von van Rhee, F. | Casper, C. | Voorhees, P. | +7

8

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Casper, C. | Chaturvedi, S. | Munshi, N. | +9

9

A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome

enthalten in: American journal of hematology | 2014

von Garcia-Manero, G. | Gartenberg, G. | Steensma, D. | +7

10

Siltuximab for multicentric Castleman's disease : a randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Oncology | 2014

von van Rhee, F. | Wong, R. | Munshi, N. | +19

ErratumIn: Lancet Oncol. 2014 Sep;15(10):417